A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...

A new ISG Provider Lens™ report says AI, cloud and 5G deployment are driving transformation in telecom, media and ...

Lung cancer treatment and outcomes are profoundly influenced by the tumor microenvironment (TME), particularly in resectable ...

Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...